10 results

• Side Effects of Xeljanz, Rinvoq and Similar Drugs May Increase Risk of Acne: Study

  November 8, 2023

  Martha Garcia

  A new study links Xeljanz, Rinvoq and similar drugs to an increased risk of developing acne.

• Cancer Risk with Xeljanz, Other JAK Inhibitors Higher Than Among Users of Older TNF Inhibitors

  May 1, 2023

  Russell Maas

• Study Questions Whether Side Effects of Xeljanz, Similar Drugs, Increase Blood Clot Risks

  September 8, 2022

  Irvin Jackson

  A new study raises doubts about whether Xeljanz and similar drugs increase the risk of blood clots.

• Skin Cancer Risk Linked to Xeljanz, Jakafi, Other JAK Inhibitors: Study

  May 18, 2022

  Irvin Jackson

  A new study links Xeljanz and similar drugs to an increased risk of skin cancer.

• Makers of Oluminant Withdraw Lupus Treatment Approval Request in Face of JAK-Inhibitor Health Risks

  January 31, 2022

  Irvin Jackson

  A request for approval for Olumiant to treat lupus has been withdrawn, and the manufacturers expect the FDA to reject an atopic dermatitis approval request in the face of growing concerns over the side effects of similar arthritis drugs like Xeljanz.

• Rinvoq Warning Label Updated to Add Cancer and Heart Risks Seen With Xeljanz Side Effects

  December 6, 2021

  Irvin Jackson

  Rinvoq will now carry label warnings on cancer and heart risks which were first discovered through a study of Xeljanz side effects.

• Eli Lilly-Funded Study Claims Side Effects of Olumiant Do Not Warrant Same Adverse Label Warnings as Xeljanz

  November 16, 2021

  Irvin Jackson

  A new study announced by Eli Lilly appears to suggest Olumiant, a rheumatoid arthritis drug, does not need the same label warnings for heart problems as Xeljanz, it's competitor.

• Xeljanz Heart Risks May Be Similar Across Other JAK Inhibitors Like Rinvoq, Oluminant: Study

  November 12, 2021

  Irvin Jackson

  A new study suggests the risk of heart problems linked to Xeljanz is similar across all other rheumatoid arthritis drugs belonging to the same class of medications.

• Xeljanz FDA Label Warning Update Adds Information About Risk of Cancer, Blood Clots and Heart Side Effects

  September 2, 2021

  Irvin Jackson

  The FDA is requiring new label warnings for Xeljanz and similar drugs, following a review which revealed links between increased risks of heart attacks, strokes, blood clots, and lymphomas, as well as an increased risk of lung cancer for current or former smokers.

• Experts, FDA Concerned Xeljanz Heart and Cancer Problems May Affect Similar Arthritis Drugs

  July 28, 2021

  Irvin Jackson

  Drugs in the same class as Xeljanz face increased scrutiny over concerns they may carry similar heart and cancer risks such as those suspected of plaguing the arthritis drug.